| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BETTER THERAPEUTICS Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| IBIO | 1,051 | +4,79 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| TRAWS PHARMA | 0,542 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,450 | -0,77 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| CARTESIAN THERAPEUTICS | 6,200 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | ||
| RECURSION PHARMACEUTICALS | 4,790 | +0,21 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | 0,00 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 284,03 | +0,17 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| MBX BIOSCIENCES | 58,54 | 0,00 % | Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential | ||
| BRAVEHEART BIO | 21,350 | 0,00 % | Stifel reiterates Buy on Braveheart Bio stock, $45 target | ||
| AMYLYX PHARMACEUTICALS | 27,780 | 0,00 % | Amylyx Pharma Q2 2026 Earnings Call Transcript | ||
| ERASCA | 14,740 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| NAUTILUS BIOTECHNOLOGY | 1,865 | -0,27 % | Roth/MKM initiates Nautilus Biotechnology stock with buy rating | ||
| EDGEWISE THERAPEUTICS | 40,350 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,470 | 0,00 % | This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday |